Microport Scientific Corp
F:MSK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Microport Scientific Corp
F:MSK
|
KY |
|
A
|
Appian Corp
F:910
|
US |
|
R
|
Royal Bank of Canada
XMUN:RYC
|
CA |
|
Indofood CBP Sukses Makmur Tbk PT
F:48I
|
ID |
|
M
|
Masterworks 082 LLC
OTC:MSWOS
|
US |
|
C
|
Costco Wholesale Corp
F:CTO
|
US |
|
T
|
TC Energy Corp
F:TRS
|
CA |
|
D
|
Digital Commodities Inc
CNSX:DIGI
|
CA |
|
M
|
Mitra Pedagang Indonesia PT Tbk
IDX:MPIX
|
ID |
|
Nintendo Co Ltd
F:NTOA
|
JP |
|
L
|
Lowe's Companies Inc
SWB:LWE
|
US |
|
J
|
J Sainsbury PLC
OTC:JSNSF
|
UK |
|
Renegade Exploration Ltd
ASX:RNX
|
AU |
|
N
|
NanoBrick Co Ltd
KOSDAQ:286750
|
KR |
|
S
|
SCI Electric PCL
SET:SCI
|
TH |
|
Endexx Corp
OTC:EDXC
|
US |
|
C
|
CopperCorp Resources Inc
F:NU0
|
CA |
|
M
|
Marubeni Corp
OTC:MARUF
|
JP |
|
A
|
ASML Holding NV
XMUN:ASME
|
NL |
|
E
|
EST Global Apparel Co Ltd
TPEX:4413
|
TW |
|
A
|
Agnico Eagle Mines Ltd
F:AE9
|
CA |
|
A
|
AI Energy PCL
SET:AIE
|
TH |
|
Jumbo SA
OTC:JUMSY
|
GR |
|
IMCD NV
OTC:IMDZF
|
NL |
Earnings Calls
Last Earnings Call
Revenue Growth: MicroPort reported first-half 2019 revenue of $393 million, up 33.9% year-on-year, with strong performances in cardiovascular, CRM, endovascular, and neurovascular segments.
Profit Surge: Net profit attributable to shareholders jumped 175.5% to $65.5 million, driven by operational growth and a one-time gain from the EP business share transfer.
CRM Business: CRM business revenue soared by 162.5% year-on-year, with the China pacemaker segment alone achieving 245% sales volume growth.
Margin Improvement: Gross profit margin rose to 71.7%, up 0.9 percentage points, due to a better product mix.
Guidance Raised: Full-year consolidated revenue growth guidance was increased from 20% to 21%, with cardiovascular business growth now expected to exceed 25%. Orthopedics growth guidance was lowered.
China Orthopedics: China orthopedics revenue grew 53.3%, significantly outpacing the global segment, which faced headwinds in the US.
Major R&D Milestones: Multiple products received regulatory approvals in China and internationally, expanding the product portfolio across cardiovascular, orthopedic, and neurovascular lines.
Centralized Procurement: Management expects price cuts from Gansu's pilot centralized procurement to be offset by higher sales volumes and increased market share.